candesartan has been researched along with Ischemic Attack, Transient in 4 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Ischemic Attack, Transient: Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with candesartan, pioglitazone, and their combination resulted in significantly reduced mRNA expression of the inflammatory markers CXCL1 and TNFalpha in vivo (P<0." | 1.35 | Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. ( Kintscher, U; Krikov, M; Müller, S; Schefe, JH; Schmerbach, K; Thoene-Reineke, C; Unger, T; Villringer, A, 2008) |
| "Therefore, 1-hour middle cerebral artery occlusion (MCAO) was followed by reperfusion." | 1.32 | The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. ( Doerfler, A; Engelhorn, T; Forsting, M; Goerike, S; Heusch, G; Okorn, C; Schulz, R, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukui, T | 1 |
| Rahman, M | 1 |
| Hayashi, K | 1 |
| Takeda, K | 1 |
| Higaki, J | 1 |
| Sato, T | 1 |
| Fukushima, M | 1 |
| Sakamoto, J | 1 |
| Morita, S | 1 |
| Ogihara, T | 1 |
| Fukiyama, K | 1 |
| Fujishima, M | 1 |
| Saruta, T | 1 |
| Engelhorn, T | 2 |
| Goerike, S | 1 |
| Doerfler, A | 2 |
| Okorn, C | 1 |
| Forsting, M | 1 |
| Heusch, G | 2 |
| Schulz, R | 2 |
| Schmerbach, K | 1 |
| Schefe, JH | 1 |
| Krikov, M | 1 |
| Müller, S | 1 |
| Villringer, A | 1 |
| Kintscher, U | 1 |
| Unger, T | 1 |
| Thoene-Reineke, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for candesartan and Ischemic Attack, Transient
| Article | Year |
|---|---|
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cerebral Hemorrhage; Cerebral Infarctio | 2003 |
3 other studies available for candesartan and Ischemic Attack, Transient
| Article | Year |
|---|---|
The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2004 |
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebra | 2006 |
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Astrocytes; Benzimidazoles; Biph | 2008 |